FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD

August 01, 2018

In This Issue

The FDA New Drug and Biologic Approvals, 2018 Midyear Review describes new molecular entities, new biologics, and select new indications by condition for those drugs and biologics approved during the first half of this year. Each summary contains information on the indication, mechanism, dosage, and clinical trials that served as the basis for the FDA approval. For more information, each drug or biologic is linked to its corresponding Medscape drug monograph.

Primary Care

Hematology/Oncology

Infectious Disease

Neurology

Pediatrics

Reference: U.S. Food and Drug Administration. Novel Drug Approvals for 2018. Accessed June 21, 2018. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DrugInnovation/ucm592464.htm

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Mary L Windle. FDA New Drug and Biologic Approvals, 2018 Midyear Review - Medscape - Aug 01, 2018.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.